OMGA - Omega Therapeutics' Cancer Program Shows Encouraging Anti Tumor Activity In Liver Cancer | Benzinga
Omega Therapeutics Inc (NASDAQ: OMGA) announced preliminary data from the initial two dose level cohorts (n=8) from Part 1 of its Phase 1/2 MYCHELANGELO I study of OTX-2002 in hepatocellular carcinoma and other solid tumors associated with the c-MYC (MYC) gene.
OTX-2002, the company's lead development candidate, is designed to pre-transcriptionally downregulate MYC, a master oncogene implicated in more than 50% of all cancers and approximately 70% of HCC cases.
MYCHELANGELO I is an ongoing Phase 1/2 open-label ...